Berdagang Gilead GILD

Gilead carta live

Asas Instrumen

Weekly Search
Weekly
Daily
Tarikh Tutup Perubahan Perubahan (%): Buka Tinggi Rendah

Berita Terkini

Frances Wang 2025 Apr 24, 16:00

How will tariffs affect forex: EUR/USD pair weakens amid trade uncertainty

Forex
Frances Wang 2025 Apr 24, 16:00

Exchange Traded Funds News: Tech-Focused ETFs Gain Traction Amid AI Boom

ETFs
Tommy Yap 2025 Apr 24, 16:00

Morning Note: US-China Trade Deadlock; Nvidia's AI Leap; Canada Votes

Morning Note CAD Forex
Frances Wang 2025 Apr 24, 16:00

Popular CFD trading platforms 2025: eToro, Plus500, IG, MT4, MT5 and more

CFD Trading
Frances Wang 2025 Apr 23, 16:00

Hang Seng Index Gains on Strong China GDP amid Trump Tariffs Uncertainty

Indices
Frances Wang 2025 Apr 23, 16:00

Forex news today: GBP/USD gains, USD/JPY declines, EUR/USD strengthens

Forex
Frances Wang 2025 Apr 23, 16:00

Trending stocks to watch: AMD, GOOG, NVDA, AMZN, MSFT

Stocks
Tommy Yap 2025 Apr 23, 16:00

Morning Note: Tariff Deadlock Grips US-China Trade; Alphabet's Report Looms; BOJ Dilemma

Morning Note Tech

Maklumat

Sebaran nilai

0.64

Spread (%)

0.6180 %

Leveraj

1:10

Faedah semalaman (Beli)

-0.0597 %

Faedah semalaman (Jual)

-0.0292 %

Mata wang

USD

Waktu perdagangan

Pasaran dibuka

Jumaat

13:31 - 19:59

Isnin

13:31-19:59

Selasa

13:31-19:59

Rabu

13:31-19:59

Khamis

13:31-19:59

Analisis dan statistik

Buka

---

Tutup Terdahulu

---

Tinggi/Rendah 52 Minggu

--- – ---

Modal pasaran

132616495104

Saham Tertunggak

1246630016

Tarikh Pendapatan (Seterusnya)

2013-01-28

Hasil Div

2025-03-28

Tarikh Selepas Dividen

2025-03-14

Kadar dividen tahunan depan

3.16

Hasil dividen tahunan depan

0.0297

EPS

0.38

Ketahui lebih lanjut mengenai instrumen ini

Gilead Gilead Sciences Inc
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.
Trustpilot